The "Deemed To Be a License" Provision of the BPCI Act; Questions and Answers; Guidance for Industry
Details
The document's own metadata, straight from the source system.
- Title
- The "Deemed To Be a License" Provision of the BPCI Act; Questions and Answers; Guidance for Industry
- Posted
- Mar 5, 2020
- Comment period
- Mar 5, 2020 – ?
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Campaigns
Organized form-letter drives, separated from organic one-off comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jul 28, 2026Comment from Jones, Jo AnnOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 23, 2026Comment from Ely SharonOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 23, 2026Comment from Smyth R.LouiseOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 22, 2026Comment from Shirey JoeOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 22, 2026Comment from Hutton JillOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 21, 2026Comment from Vanek SaraOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 21, 2026Comment from lindgren KristenOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 20, 2026Comment from welsh karenOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 18, 2026Comment from Norelli RitaOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment → - Jul 16, 2026Comment from Dixson JillOpposeIndividual
A healthcare prescriber opposes the FDA's reclassification of desiccated thyroid extract (DTE) as a biologic. The commenter argues that this change restricts patient access to an essential therapy, reduces clinical choice, and is based on a shift in regulatory posture rather than new safety data.
Read comment →